Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 878.15M |
| Revenue (ttm) | 303.80M |
| Net Income (ttm) | -105.83M |
| Shares Out | 235.43M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | 12.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,201,368 |
| Open | 3.810 |
| Previous Close | 3.790 |
| Day's Range | 3.675 - 3.830 |
| 52-Week Range | 0.693 - 4.030 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 6.86 (+83.91%) |
| Earnings Date | Nov 6, 2025 |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD... [Read more]
Financial Performance
In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price target is $6.86, which is an increase of 83.91% from the latest price.
News
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Esperion Therapeutics, Inc. ( ESPR) Jefferies London Healthcare Conference 2025 November 18, 2025 3:00 AM EST Company Participants Benjamin Halladay - Chief Financial Officer Conference Call Particip...
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercializa...
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide rang...
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript
Esperion Therapeutics, Inc. ( ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST Company Participants Sheldon Koen...
Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability
Esperion Therapeutics remains a buy despite market skepticism, recent stock offering, and underwhelming Q3 earnings, supported by strong cardiovascular drug franchises. ESPR's profitability timeline i...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Es...
Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. ( ESPR) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Alina Venezia Sheldon Koenig - President, CEO & Director Benjamin Halladay - Chief Financia...
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientifi...
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.
Esperion Announces Pricing of Public Offering of Common Stock
ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing...
Esperion Announces Proposed Public Offering of Common Stock
ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing...
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Re...
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL Third Largest Global Market for Cardiovascular Prevention Represents Significant...
Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cantor Global Healthcare Conference 2025 September 3, 2025 9:45 AM EDT Company Participants Benjamin Halladay - Chief Financial Officer Sheldon Koenig - Pres...
Top 2 Health Care Stocks That May Plunge This Month
As of Sept. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –
Esperion (ESPR) Q2 Revenue Jumps 12%
Esperion (ESPR) Q2 Revenue Jumps 12%
Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Off...
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – ...
Esperion to Report Second Quarter 2025 Financial Results on August 5
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.
Esperion Appoints Craig Thompson to Board of Directors
Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?
Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Mana...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limite...
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Confer...